MyDiabetes IQ - AI-powered decision support tool for diabetes clinicians - Trial ISRCTN17422256
Access comprehensive clinical trial information for ISRCTN17422256 through Pure Global AI's free database. This phase not specified trial is sponsored by MyWay Digital Health Ltd and is currently status unknown. The study focuses on Diabetes mellitus. Target enrollment is 19 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ISRCTN Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
MyWay Digital Health Ltd
National Institute for Health Research
Timeline & Enrollment
N/A
Aug 02, 2021
Jul 28, 2023
Summary
Primary hypothesis: MyDiabetes IQ (MDIQ) is safe within both simulated and real-world clinical environments. Secondary hypotheses: MDIQ is usable; MDIQ is useful; MDIQ has an impact on clinician prescribing and diagnosing; MDIQ has an impact on patient metabolic outcomes.
ICD-10 Classifications
Data Source
ISRCTN Registry
ISRCTN17422256
Non-Device Trial